BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells

BRAF(V600E) is the most frequent oncogenic mutation identified in papillary thyroid cancer (PTC). In PTC patients who do not respond to standard treatment, BRAF inhibitors are currently tested as alternative strategies. However, as observed for other targeted therapies, patients eventually develop d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonaldi, Elisa, Gargiuli, Chiara, De Cecco, Loris, Micali, Arianna, Rizzetti, Maria Grazia, Greco, Angela, Borrello, Maria Grazia, Minna, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198461/
https://www.ncbi.nlm.nih.gov/pubmed/34072194
http://dx.doi.org/10.3390/ijms22115744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198461/
https://www.ncbi.nlm.nih.gov/pubmed/34072194
http://dx.doi.org/10.3390/ijms22115744

Ejemplares similares